Literature DB >> 12124175

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.

Stefano J Mandriota1, Kevin J Turner, David R Davies, Paul G Murray, Neil V Morgan, Heidi M Sowter, Charles C Wykoff, Eamonn R Maher, Adrian L Harris, Peter J Ratcliffe, Patrick H Maxwell.   

Abstract

Mutations in the von Hippel-Lindau (VHL) gene are associated with hereditary and sporadic clear cell renal carcinoma. VHL acts in a ubiquitin ligase complex regulating hypoxia-inducible factor-1 (HIF-1), but the link between this function and cancer development is unclear. Here we show that in the kidneys of patients with VHL disease, HIF activation is an early event occurring in morphologically normal single cells within the renal tubules. In comparison, dysplastic lesions, cystic lesions, and tumors showed evidence of additional mechanisms that amplify HIF activation. Detection of cells with constitutive HIF activation identified a large number of previously unrecognized foci of VHL inactivation. In proximal tubules these were almost entirely unicellular, whereas multicellular foci were almost exclusively seen in the distal nephron.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124175     DOI: 10.1016/s1535-6108(02)00071-5

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  190 in total

Review 1.  Renal cancer: oxygen meets metabolism.

Authors:  Volker H Haase
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

2.  Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.

Authors:  Wenhua Gao; Wei Li; Tengfei Xiao; Xiaole Shirley Liu; William G Kaelin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-12       Impact factor: 11.205

Review 3.  Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.

Authors:  Vaithinathan Selvaraju; Narasimham L Parinandi; Ram Sudheer Adluri; Joshua W Goldman; Naveed Hussain; Juan A Sanchez; Nilanjana Maulik
Journal:  Antioxid Redox Signal       Date:  2013-10-31       Impact factor: 8.401

Review 4.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.

Authors:  Gregg L Semenza
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

5.  Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

Authors:  A Ari Hakimi; Ying-Bei Chen; James Wren; Mithat Gonen; Omar Abdel-Wahab; Adriana Heguy; Han Liu; Shugaku Takeda; Satish K Tickoo; Victor E Reuter; Martin H Voss; Robert J Motzer; Jonathan A Coleman; Emily H Cheng; Paul Russo; James J Hsieh
Journal:  Eur Urol       Date:  2012-09-27       Impact factor: 20.096

6.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

7.  Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin.

Authors:  Sarah K Harten; Deepa Shukla; Ravi Barod; Alexander Hergovich; Maria S Balda; Karl Matter; Miguel A Esteban; Patrick H Maxwell
Journal:  Mol Biol Cell       Date:  2008-12-10       Impact factor: 4.138

8.  DNMT3a epigenetic program regulates the HIF-2α oxygen-sensing pathway and the cellular response to hypoxia.

Authors:  Gabriel Lachance; James Uniacke; Timothy E Audas; Chet E Holterman; Aleksandra Franovic; Josianne Payette; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-09       Impact factor: 11.205

9.  Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.

Authors:  Jiabin An; Matthew B Rettig
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

10.  Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Authors:  Á Ordóñez-Navadijo; E Fuertes-Yebra; B Acosta-Iborra; E Balsa; A Elorza; J Aragonés; M O Landazuri
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.